Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab and Milk OIT for Milk Allergy
NCT01157117Phase 2Completed
- Start
- Aug 2010
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omalizumab in Milk allergy (MA) (3 arms). Primary endpoint: Percentage of Subjects Developing Clinical Tolerance to Milk at Month 32. Started Aug 2010; status: completed.
02
Drugs
omalizumab
03
Conditions
Milk allergy (MA)
Beyond the preview
Go deeper on NCT01157117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01157117.